Published in Nat Med on March 19, 2006
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol (2010) 1.48
Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy. Pediatr Nephrol (2009) 1.45
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev (2009) 1.19
Network-assisted protein identification and data interpretation in shotgun proteomics. Mol Syst Biol (2009) 1.19
High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clin Appl (2007) 1.17
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One (2010) 1.12
The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics (2009) 1.11
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther (2009) 1.08
Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One (2011) 1.07
Hydronephrosis due to pelviureteric junction narrowing: Utility of urinary enzymes to predict the need for surgical management and follow-up. J Indian Assoc Pediatr Surg (2012) 1.05
Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl (2008) 1.00
The proteogenomic path towards biomarker discovery. Pediatr Transplant (2008) 1.00
Congenital ureteropelvic junction obstruction: human disease and animal models. Int J Exp Pathol (2010) 0.99
Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One (2010) 0.89
Noninvasive Staging of Kidney Dysfunction Enabled by Renal-Clearable Luminescent Gold Nanoparticles. Angew Chem Int Ed Engl (2016) 0.89
Non-invasive markers of ureteropelvic junction obstruction. World J Urol (2007) 0.88
Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics (2012) 0.88
Protein Bioinformatics Infrastructure for the Integration and Analysis of Multiple High-Throughput "omics" Data. Adv Bioinformatics (2010) 0.87
Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol (2009) 0.87
An individual urinary proteome analysis in normal human beings to define the minimal sample number to represent the normal urinary proteome. Proteome Sci (2012) 0.86
Challenges and opportunities for discovery of disease biomarkers using urine proteomics. Pediatr Int (2011) 0.85
Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol (2014) 0.85
Proteomics and opportunities for clinical translation in urological disease. J Urol (2009) 0.84
Obstructive renal injury: from fluid mechanics to molecular cell biology. Open Access J Urol (2010) 0.84
Chronic partial ureteral obstruction and the developing kidney. Pediatr Radiol (2007) 0.83
The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front Immunol (2016) 0.83
Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One (2012) 0.82
The nephrologist of tomorrow: towards a kidney-omic future. Pediatr Nephrol (2016) 0.81
Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. PLoS One (2016) 0.80
Deconvoluting the 'omics' for organ transplantation. Curr Opin Organ Transplant (2009) 0.80
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med (2014) 0.79
Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol (2008) 0.79
Urinary levels of TGF β-1 and of cytokines in patients with prenatally detected nephrouropathies. Pediatr Nephrol (2011) 0.77
Early markers of obesity-related renal injury in childhood. Pediatr Nephrol (2014) 0.77
Prognostic factors and biomarkers of congenital obstructive nephropathy. Pediatr Nephrol (2015) 0.77
Application of Proteomic Analysis to Renal Disease in the Clinic. Proteomics Clin Appl (2009) 0.76
Congenital urinary tract obstruction: the long view. Adv Chronic Kidney Dis (2015) 0.76
Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases. Int J Clin Exp Pathol (2008) 0.76
Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy. Mol Cell Proteomics (2014) 0.76
Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease. J Neuropathol Exp Neurol (2016) 0.75
Renal injury in neonates: use of "omics" for developing precision medicine in neonatology. Pediatr Res (2016) 0.75
A capillary electrophoresis coupled to mass spectrometry pipeline for long term comparable assessment of the urinary metabolome. Sci Rep (2016) 0.75
Fibroproliferative response to urothelial failure obliterates the ureter lumen in a mouse model of prenatal congenital obstructive nephropathy. Sci Rep (2016) 0.75
Urinary Proteomics Yield Pathological Insights for Ureteropelvic Junction Obstruction. Mol Cell Proteomics (2016) 0.75
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS One (2011) 0.75
Urinary proteome analysis and the management of ureteropelvic junction obstruction. Pediatr Nephrol (2010) 0.75
Posterior urethral valves: renal failure and prenatal treatment. Int J Nephrol (2011) 0.75
12. The Urinary Proteomics: A Tool to Discover New and Potent Biomarkers for Kidney Damage. EJIFCC (2009) 0.75
Light-Emitting Agents for Noninvasive Assessment of Kidney Function. ChemistryOpen (2017) 0.75
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother (2009) 2.86
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (2008) 2.64
Separate ion pathways in a Cl-/H+ exchanger. J Gen Physiol (2005) 2.34
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest (2011) 2.25
Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res (2008) 2.12
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Urine in clinical proteomics. Mol Cell Proteomics (2008) 2.05
Obstructive nephropathy: insights from genetically engineered animals. Kidney Int (2005) 1.97
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. Cell (2004) 1.79
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res (2002) 1.71
Renal phenotypes related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. J Am Soc Nephrol (2005) 1.70
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol (2002) 1.63
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int (2005) 1.63
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. J Am Soc Nephrol (2007) 1.56
Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res (2009) 1.56
GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr Nephrol (2006) 1.55
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res (2007) 1.52
LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol (2007) 1.51
Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol (2010) 1.48
Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics (2007) 1.47
Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet (2014) 1.44
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood (2007) 1.44
Urinary proteome analysis to exclude severe vesicoureteral reflux. Pediatrics (2012) 1.42
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes (2003) 1.39
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood (2004) 1.33
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int (2004) 1.29
Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol (2006) 1.29
Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology (2011) 1.28
Estimation of glomerular filtration rate in children. Pediatr Nephrol (2002) 1.26
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis (2007) 1.26
Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev (2005) 1.26
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant (2005) 1.24
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis (2005) 1.24
Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) (2004) 1.23
Urinary proteomics for prediction of preeclampsia. Hypertension (2011) 1.20
Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev (2009) 1.19
Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway. J Biol Chem (2002) 1.17
Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics (2010) 1.16
Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A (2003) 1.16
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int (2005) 1.13
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int (2009) 1.12
Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis (2005) 1.12
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One (2010) 1.12
Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications (2005) 1.12
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl (2010) 1.12
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut (2012) 1.11
The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics (2009) 1.11
Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha. J Biol Chem (2003) 1.11